The fixed drug combination (FDC) of Vildagliptin and Dapagliflozin exhibits a synergistic effect by combining the DPP-4 inhibition of Vildagliptin with the SGLT2 inhibition of Dapagliflozin. The FDC medication enhances glycemic control through complementary mechanisms of action. This synergistic effect can improve blood sugar management and potentially better overall outcomes for individuals with type 2 diabetes. Join Dr. K.M. Suryanaryan, Dr. R. Santosh, and Dr. Chetan P. Shah on July 6 at 8:00 p.m. to learn more about their perspectives on the FDC.
Dr. Chetan p Shah
Interventional Cardiologist & Arrhythmia Specialist, Visiting Professor of Cardiology, Michigan State University, USA, Honorable Interventional Cardiologist at various Hospitals in Mumbai
Dr. K M Suryanaryan
Senior Professor in Dept of Endocrinology, MS Ramaiah Medical College & Hospitals, Bengaluru
Dr. R. Santosh
MD DM Endocrinology FIAMS FACE Consultant Endocrinologist Magna Centres For Obesity Diabetes And Endocrinology and Endocrinologist, Hyderabad
